Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation
- Conditions
- H1N1 Influenza
- Registration Number
- NCT01008683
- Lead Sponsor
- Hadassah Medical Organization
- Brief Summary
Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines.
In these patients the investigators will measure the specific antibody production.
- Detailed Description
Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines. Two doses will be given, in 3-week interval.
In these patients we will measure the specific antibody production. Blood sample 5 ml will be drawn before the first vaccine, before the second, and 3-4 weeks after the 2nd dose.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
- Stem cell and and heart transplant patients who will receive pandemic H1N1 influenza vaccination according to the clinical guidelines.
Exclusion Criteria
- Patients with unstable grafts.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hadassah Medical Organization
🇮🇱Jerusalem, Israel